Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Jiangsu Weiqida Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active drug voronosene fumarate approved and issued by the State Drug Administration. Voronolacin fumarate is a potassium ion competitive acid blocker (P-CAB) that can inhibit gastric acid production and damage to the upper gastrointestinal mucosa. It is mainly used in the treatment of reflux esophagitis and Helicobacter pylori infection.

Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Jiangsu Weiqida Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active drug voronosene fumarate approved and issued by the State Drug Administration. Voronolacin fumarate is a potassium ion competitive acid blocker (P-CAB) that can inhibit gastric acid production and damage to the upper gastrointestinal mucosa. It is mainly used to treat reflux esophagitis and Helicobacter pylori infection.